51 related articles for article (PubMed ID: 2576469)
1. [Somatostatin-like activity (SLI) in the blood during metformin treatment of obese patients with diabetes mellitus type 2].
Lawecki J; Stryjek-Kamińska D; Schusdziarra V
Pol Arch Med Wewn; 1989 Mar; 81(3):183-8. PubMed ID: 2576469
[TBL] [Abstract][Full Text] [Related]
2. Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in noninsulin-dependent diabetes mellitus: evidence for more than one mechanism of action.
Gutniak M; Grill V; Efendić S
J Clin Endocrinol Metab; 1986 Jan; 62(1):77-83. PubMed ID: 2866196
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
DeFronzo RA; Barzilai N; Simonson DC
J Clin Endocrinol Metab; 1991 Dec; 73(6):1294-301. PubMed ID: 1955512
[TBL] [Abstract][Full Text] [Related]
4. Plasma somatostatin-like immunoreactivity responses to a mixed meal and the heterogeneity in healthy and non-insulin-dependent (NIDDM) diabetics.
Miyazaki K; Funakoshi A; Ibayashi H
Endocrinol Jpn; 1986 Feb; 33(1):51-9. PubMed ID: 2873028
[TBL] [Abstract][Full Text] [Related]
5. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
6. Fasting and postprandial concentrations of somatostatin-28 and somatostatin-14 in type II diabetes in men.
D'Alessio DA; Ensinck JW
Diabetes; 1990 Oct; 39(10):1198-202. PubMed ID: 1976558
[TBL] [Abstract][Full Text] [Related]
7. Basal and meal-induced somatostatin-like immunoreactivity in healthy subjects and in IDDM and totally pancreatectomized patients. Effects of acute blood glucose normalization.
Gutniak M; Grill V; Wiechel KL; Efendić S
Diabetes; 1987 Jul; 36(7):802-7. PubMed ID: 2884157
[TBL] [Abstract][Full Text] [Related]
8. Response of plasma somatostatin-like immunoreactivity (SLI) to a 75 g oral glucose tolerance test in normal subjects and patients with impaired glucose tolerance.
Itoh M; Hirooka Y; Nihei N
Acta Endocrinol (Copenh); 1983 Dec; 104(4):468-74. PubMed ID: 6140806
[TBL] [Abstract][Full Text] [Related]
9. Plasma somatostatin-like immunoreactivity and somatostatin-28 levels in obese men.
Peracchi M; Carola F; Cavagnini F; Benti R; Bareggi B; Baccalaro G; Basilisco G
J Endocrinol Invest; 1998 Jan; 21(1):20-3. PubMed ID: 9633018
[TBL] [Abstract][Full Text] [Related]
10. A stimulating effect of glucose on somatostatin release is impaired in noninsulin-dependent diabetes mellitus.
Grill V; Gutniak M; Roovete A; Efendić S
J Clin Endocrinol Metab; 1984 Aug; 59(2):293-7. PubMed ID: 6145723
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Diabet Med; 2009 Jun; 26(6):649-54. PubMed ID: 19538242
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the hormonal status of somatostatin in man.
Zyznar ES; Pietri AO; Harris V; Unger RH
Diabetes; 1981 Oct; 30(10):883-6. PubMed ID: 6115787
[TBL] [Abstract][Full Text] [Related]
13. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria.
Hollenbeck CB; Johnston P; Varasteh BB; Chen YD; Reaven GM
Diabete Metab; 1991; 17(5):483-9. PubMed ID: 1752350
[TBL] [Abstract][Full Text] [Related]
14. Free somatostatin in the circulation: amounts and molecular sizes of somatostatin-like immunoreactivity in portal, aortic, and vena caval plasma of fasting and meal-stimulated dogs.
Schusdziarra V; Zyznar E; Rouiller D; Harris V; Unger RH
Endocrinology; 1980 Nov; 107(5):1572-6. PubMed ID: 6107241
[TBL] [Abstract][Full Text] [Related]
15. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
16. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin.
Dandona P; Aljada A; Ghanim H; Mohanty P; Tripathy C; Hofmeyer D; Chaudhuri A
J Clin Endocrinol Metab; 2004 Oct; 89(10):5043-7. PubMed ID: 15472203
[TBL] [Abstract][Full Text] [Related]
17. Circulating somatostatin concentrations in healthy and non-insulin-dependent (type II) diabetic subjects.
Conlon JM; McCulloch AJ; Alberti KG
Diabetes; 1983 Aug; 32(8):723-9. PubMed ID: 6347769
[TBL] [Abstract][Full Text] [Related]
18. Postprandial paradoxical IGFBP-1 response in obese patients with Type 2 diabetes.
Lehtihet M; Efendic S; Brismar K
Clin Sci (Lond); 2008 Sep; 115(5):167-74. PubMed ID: 18208402
[TBL] [Abstract][Full Text] [Related]
19. The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes.
Bi Y; Tong GY; Yang HJ; Cai MY; Ma JH; Liang J; Xin B; Miao H; Peng ZH; Zhu DL
Diabetes Metab Res Rev; 2013 Nov; 29(8):664-72. PubMed ID: 23955995
[TBL] [Abstract][Full Text] [Related]
20. Plasma somatostatin and vasoactive intestinal polypeptide responses to an oral mixed test meal in obese patients.
Barreca T; Franceschini R; Messina V; Cataldi A; Salvemini M; Rolandi E
Horm Res; 1989; 31(5-6):234-7. PubMed ID: 2575574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
